Kenneth Widder is listed as an executive officer, director, and promoter on 7 SEC Form D filings by 4 issuers between Jul 2009 and Aug 2021: SYDNEXIS, INC. (Del Mar, CA — industry reported as "Other" — 2017–2021; $45.8M reported sold to 30 investors), OrphoMed, Inc. (Mill Valley, CA — biotechnology — 2017; $21.8M reported sold to 17 investors), Evoke Pharma Inc (San Diego, CA — biotechnology — 2010; $6M reported sold to 20 investors) and FEMTA PHARMACEUTICALS, INC. (San Diego, CA — pharmaceuticals — 2009–2010; $2.2M reported sold to 5 investors).
What this means A repeat sponsor — 4 separate companies raised money with this person listed as executive officer, director, and promoter, over about 12 years. Across those companies the filings report $75.7M sold in total.
Listed alongside Jay Short (3 shared filings), Jim Woody (3 shared filings), Per Peterson (3 shared filings), Stephen Keane (3 shared filings), Mary Jacqueline Johnson (2 shared filings) and 18 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kenneth. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 7 public filings for Kenneth Widder and found 10 differences, 1 worth asking the sponsor about: Amount sold went down between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.